The influence of anti-inflammatory and immunosuppressant drugs on Nystatin induced oedema.
D000818:Animals; D000893:Anti-Inflammatory Agents / Q000494:pharmacology*; D000903:Antibiotics, Antineoplastic / Q000494:pharmacology; D001168:Arthritis / Q000188:drug therapy; D001241:Aspirin / Q000494:pharmacology; D001379:Azathioprine / Q000494:pharmacology; D002701:Chloramphenicol / Q000494:pharmacology; D003520:Cyclophosphamide / Q000494:pharmacology; D003907:Dexamethasone / Q000494:pharmacology; D004336:Drug Antagonism; D004487:Edema / Q000139:chemically induced / Q000188:drug therapy*; D006854:Hydrocortisone / Q000494:pharmacology; D007166:Immunosuppressive Agents / Q000494:pharmacology*; D007213:Indomethacin / Q000494:pharmacology; D007249:Inflammation / Q000139:chemically induced / Q000188:drug therapy*; D008297:Male; D008528:Mefenamic Acid / Q000494:pharmacology; D015122:Mercaptopurine / Q000494:pharmacology; D009761:Nystatin / Q000037:antagonists & inhibitors*; D010648:Phenylacetates / Q000494:pharmacology; D010653:Phenylbutazone / Q000494:pharmacology; D011239:Prednisolone / Q000494:pharmacology; D051381:Rats; D012293:Rifampin / Q000494:pharmacology; D014221:Triamcinolone / Q000494:pharmacology
D000893:Anti-Inflammatory Agents; D000903:Antibiotics, Antineoplastic; D007166:Immunosuppressive Agents; D010648:Phenylacetates; D009761:Nystatin; D014221:Triamcinolone; D008528:Mefenamic Acid; D002701:Chloramphenicol; D003907:Dexamethasone; D003520:Cyclophosphamide; D011239:Prednisolone; D015122:Mercaptopurine; D010653:Phenylbutazone; D001379:Azathioprine; D001241:Aspirin; D012293:Rifampin; D006854:Hydrocortisone; D007213:Indomethacin